2. Academic Validation
  3. Leukemia inhibitory factor is a therapeutic target for renal interstitial fibrosis

Leukemia inhibitory factor is a therapeutic target for renal interstitial fibrosis

  • EBioMedicine. 2022 Nov 3;86:104312. doi: 10.1016/j.ebiom.2022.104312.
Shihui Xu 1,  Xiaobing Yang 1,  Qingzhou Chen 1,  Zhuoliang Liu 1,  Ying Chen 1,  Xiaotian Yao 1,  An Xiao 1,  Jianwei Tian 1,  Liling Xie 1,  Miaomiao Zhou 1,  Zheng Hu 1,  Fengxin Zhu 1,  Xin Xu 1,  Fanfan Hou 2,  Jing Nie 3
Affiliations

Affiliations

  • 1 Division of Nephrology, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • 2 Division of Nephrology, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: ffhouguangzhou@163.com.
  • 3 Division of Nephrology, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: niejing@smu.edu.cn.
PMID: 36335669 DOI: 10.1016/j.ebiom.2022.104312
Abstract

Background: The role of the IL6 family members in organ fibrosis, including renal interstitial fibrosis (TIF), has been widely explored. However, few studies have ever simultaneously examined them in the same cohort of patients. Besides, the role of Leukemia Inhibitory Factor (LIF) in TIF remains unclear.

Methods: RNA-seq data of kidney biopsies from chronic kidney disease (CKD) patients, in both public databases and our assays, were used to analyze transcript levels of IL6 family members. Two TIF mouse models, the unilateral ureteral obstruction (UUO) and the ischemia reperfusion injury (IRI), were employed to validate the finding. To assess the role of LIF in vivo, short hairpin RNA, lenti-GFP-LIF was used to knockdown LIF receptor (LIFR), overexpress LIF, respectively. LIF-neutralizing antibody was used in therapeutic studies. Whether urinary LIF could be used as a promising predictor for CKD progression was investigated in a prospective observation patient cohort.

Findings: Among IL6 family members, LIF is the most upregulated one in both human and mouse renal fibrotic lesions. The mRNA level of LIF negatively correlated with EGFR with the strongest correlation and the smallest P value. Baseline urinary concentrations of LIF in CKD patients predict the risk of CKD progression to end-stage kidney disease by Kaplan-Meier analysis. In mouse TIF models, knockdown of LIFR alleviated TIF; conversely, overexpressing LIF exacerbated TIF. Most encouragingly, visible efficacy against TIF was observed by administering LIF-neutralizing Antibodies to mice. Mechanistically, LIF-LIFR-EGR1 axis and Sonic Hedgehog signaling formed a vicious cycle between fibroblasts and proximal tubular cells to augment LIF expression and promote the pro-fibrotic response via ERK and STAT3 activation.

Interpretation: This study discovered that LIF is a noninvasive biomarker for the progression of CKD and a potential therapeutic target of TIF.

Fundings: Stated in the Acknowledgements section of the manuscript.

Keywords

Chronic kidney disease; Fibroblast activation; IL6 family; LIF; Renal fibrosis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z